Indiana University Dermatology Clinical Trials

Vitiligo is an autoimmune disease that causes the immune system to destroy pigment-producing skin cells, resulting in white patches. Current dermatology clinical trials in Indiana include a trial of a study drug for non-segmental vitiligo (NSV). Participants will receive either the study drug or a placebo for 48 weeks (about 11 months), followed by the study drug for 112 weeks (about 2 years).

Additional trials are examining other treatments for NSV. This second study drug is under study for its effectiveness, and another trial evaluates a third study drug. In the research study, participants will take the medicine or a placebo and undergo extensive monitoring over 26 months (about 2 years) through regular visits and various medical tests to assess the treatment’s safety and impact.